5. Immunotherapy


Back to Package

Only available as part of a package

Outline:

  • Checkpoint Inhibitors
  • Anti-Programmed Cell Death Protein 1 (PD-1)
  • Anti-Programmed Death-Ligand 1 (PD-L1)
  • Anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) 
  • Lymphocyte Activation Gene 3 (LAG-3) 
  • General Immune Checkpoint Inhibitor Toxicities 
  • Immune-Related Adverse Events (irAEs)
  • Viral Therapy 
  • Interferons 
  • Interleukins

After completing this educational activity, participants should be able to:

  • List the various classes of therapeutic agents
  • Describe the unique characteristics of each class of immunotherapies including:
    • Dose limitations
    • Common toxicities
    • Black box warnings

Michela Altergott

PharmD

St. Luke’s Cancer Institute Boise

Dr. Altergott is the lead oncology pharmacist at St. Luke’s Cancer Institute in Boise, Idaho, as well as a lecturer at Idaho State University. She spearheaded a resident project to create a new clinical pharmacist position in the medical oncology clinic to work directly with the oncologists, advanced practice providers, and patients. She co-published a research article in Oncology Issues in 2021 and has participated in research presented at several conferences, including the 2021 Mountain States Residency Conference and 2021 Hematology Oncology Pharmacy Association Spring Conference. She has served on St. Luke’s Medication Safety Committee since 2016 and the IV Room Task Force Committee since 2019.
Dr. Altergott has no relevant financial relationships to disclose.

Key:

Complete
Failed
Available
Locked
Checkpoint Inhibitors (10 min.)
Open to view video.
Open to view video.
You must register to access.
Checkpoint Inhibitors - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Anti-Programmed Cell Death Protein 1 (PD-1) (9 min.)
Open to view video.
Open to view video.
You must register to access.
Anti-Programmed Cell Death Protein 1 (PD-1) - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) (11 min.)
Open to view video.
Open to view video.
You must register to access.
Anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Viral Therapy (10 min.)
Open to view video.
Open to view video.
You must register to access.
Viral Therapy - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Clinical Pearls (5 min.)
Open to view video.
Open to view video.
You must register to access.
Immunotherapy - Post Test
6 Questions  |  3 attempts  |  5/6 points to pass
6 Questions  |  3 attempts  |  5/6 points to pass This post test counts towards your CE Certificate. You must answer at least 5 of 6 questions correctly to earn credit for this module. You have 3 attempts to pass the Post Test.
You must register to access.